Bacterial phenotype variants in group B streptococcal toxic shock syndrome

Emerging Infectious Diseases

Volumn 15, Issue 2, 2009, Pages 223-232

  Sendi, Parham ^a,b,g   Johansson, Linda ^a   Dahesh, Samira ^c   Van Sorge, Nina M ^c   Darenberg, Jessica ^d   Norgren, Mari ^e   Sjölin, Jan ^f   Nizet, Victor ^c   Norrby Teglund, Anna ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^e UMEÅ UNIVERSITY   (Sweden)

^f UPPSALA UNIVERSITY   (Sweden)

^g UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CLINDAMYCIN; CORTICOSTEROID; GENTAMICIN; HYPERTENSIVE FACTOR; IMMUNOGLOBULIN; INTERLEUKIN 8; PENICILLIN G;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTEREMIA; BACTERIAL GENE; BACTERIAL GROWTH; BACTERIAL MEMBRANE; CASE REPORT; CLINICAL FEATURE; CONTROLLED STUDY; FOLLOW UP; GENETIC ANALYSIS; GENETIC VARIABILITY; HEMOLYSIS; HOST; HUMAN; IN VITRO STUDY; MALE; MOLECULAR CLONING; MORTALITY; MOUSE; MURINAE; NECROTIZING FASCIITIS; NONHUMAN; PHAGOCYTOSIS; PHENOTYPE; SEPTIC SHOCK; SINGLE DRUG DOSE; STREPTOCOCCUS AGALACTIAE; TISSUE CULTURE; TOXIC SHOCK SYNDROME; TREATMENT OUTCOME;

ANIMALS; BACTERIAL CAPSULES; BACTERIAL PROTEINS; FASCIITIS, NECROTIZING; GENETIC VARIATION; HEMOLYSIS; HUMANS; MALE; MICE; MIDDLE AGED; NEUTROPHILS; OPSONIN PROTEINS; PHAGOCYTOSIS; PHENOTYPE; REPRESSOR PROTEINS; SHOCK, SEPTIC; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS AGALACTIAE;

EID: 63849139027     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid1502.080990     Document Type: Article

References (38)

1. Phares CR, Lynfield R, Farley MM, Mohle-Boetani J, Harrison LH, Petit S, et al. Epidemiology of invasive group B streptococcal disease in the United States, 1999-2005. JAMA. 2008;299:2056-65. DOI: 10.1001/jama.299.17.2056
2. Lang ME, Vaudry W, Robinson JL. Case report and literature review of late-onset group B streptococcal disease manifesting as necrotiz- ing fasciitis in preterm infants: is this a new syndrome? Clin Infect Dis. 2003;37:e132-5. DOI: 10.1086/378892
3. Wong CH, Kurup A, Tan KC, Group B. Streptococcus necrotiz- ing fasciitis: an emerging disease? Eur J Clin Microbiol Infect Dis. 2004;23:573-5.
4. Marques MB, Kasper DL, Pangburn MK, Wessels MR. Prevention of C3 deposition by capsular polysaccharide is a virulence mechanism of type III group B streptococci. Infect Immun. 1992;60:3986-93.
5. Spellerberg B, Pohl B, Haase G, Martin S, Weber-Heynemann J, Lutticken R. Identification of genetic determinants for the hemolytic activity of Streptococcus agalactiae by ISS7 transposition. J Bacte- riol. 1999;181:3212-9.
6. Pritzlaff CA, Chang JC, Kuo SP, Tamura GS, Rubens CE, Nizet V. Genetic basis for the beta-haemolytic/cytolytic activity of group B Streptococcus. Mol Microbiol. 2001;39:23 6-47. DOI: 10.1046/ j.1365-2958.2001.02211.x
7. Nizet V, Gibson RL, Chi EY, Framson PE, Hulse M, Rubens CE. Group B streptococcal beta-hemolysin expression is associated with injury of lung epithelial cells. Infect Immun. 1996;64:3818-26.
8. Gibson RL, Nizet V, Rubens CE. Group B streptococcal beta- hemolysin promotes injury of lung microvascular endothelial cells. Pediatr Res. 1999;45:626-34. DOI: 10.1203/00006450-199905010-00003
9. Nizet V, Kim KS, Stins M, Jonas M, Chi EY, Nguyen D, et al. Invasion of brain microvascular endothelial cells by group B streptococci. Infect Immun. 1997;65:5074-81.
10. Puliti M, Nizet V, von Hunolstein C, Bistoni F, Mosci P, Orefici G, et al. Severity of group B streptococcal arthritis is correlated with beta-hemolysin expression. J Infect Dis. 2000;182:824-32. DOI: 10.1086/315773
11. Doran KS, Chang JC, Benoit VM, Eckmann L, Nizet V. Group B streptococcal beta-hemolysin/cytolysin promotes invasion of human lung epithelial cells and the release of interleukin-8. J Infect Dis. 2002;185:196-203. DOI: 10.1086/338475
12. Doran KS, Liu GY, Nizet V. Group B streptococcal beta-hemolysin/ cytolysin activates neutrophil signaling pathways in brain endothe- lium and contributes to development of meningitis. J Clin Invest. 2003;112:736-44.
13. Ring A, Braun JS, Pohl J, Nizet V, Stremmel W, Shenep JL. Group B streptococcal beta-hemolysin induces mortality and liver injury in experimental sepsis. J Infect Dis. 2002;185:1745-53. DOI: 10.1086/340818
14. Hensler ME, Liu GY, Sobczak S, Benirschke K, Nizet V, Heldt GP. Virulence role of group B Streptococcus beta-hemolysin/cytolysin in a neonatal rabbit model of early-onset pulmonary infection. J Infect Dis. 2005;191:1287-91. DOI: 10.1086/428946
15. Spellerberg B, Martin S, Brandt C, Lutticken R. The cyl genes of Streptococcus agalactiae are involved in the production of pigment. FEMS Microbiol Lett. 2000;188:125-8. DOI: 10.1111/J.1574-6968.2000.tb09182.x
16. Liu GY, Doran KS, Lawrence T, Turkson N, Puliti M, Tissi L, et al. Sword and shield: linked group B streptococcal beta-hemolysin/ cytolysin and carotenoid pigment function to subvert host phagocyte defense. Proc Natl Acad Sci U S A. 2004;101:14491-6. DOI: 10.1073/pnas.0406143101
17. Stanley J, Desai M, Xerry J, Tanna A, Efstratiou A, George R. High- resolution genotyping elucidates the epidemiology of group A streptococcus outbreaks. J Infect Dis. 1996;174:500-6.
18. Buchanan JT, Stannard JA, Lauth X, Ostland VE, Powell HC, West-erman ME, et al. Streptococcus iniae phosphoglucomutase is a virulence factor and a target for vaccine development. Infect Immun. 2005;73:693 5-44. DOI: 10.1128/IAI.73.10.6935-6944.2005
19. Lewis AL, Nizet V, Varki A. Discovery and characterization of sialic acid O-acetylation in group B Streptococcus. Proc Natl Acad Sci U S A. 2004;101:11123-8. DOI: 10.1073/pnas.0403010101
20. Tettelin H, Masignani V, Cieslewicz MJ, Donati C, Medini D, Ward NL, et al. Genome analysis of multiple pathogenic isolates of Streptococcus agalactiae: implications for the microbial "pan-genome.". Proc Natl Acad Sci USA. 2005;102:13950-5. DOI: 10.1073/pnas.0506758102
21. Jeng A, Sakota V, Li Z, Datta V, Beall B, Nizet V. Molecular genetic analysis of a group A Streptococcus operon encoding serum opacity factor and a novel fibronectin-binding protein, SfbX. J Bacteriol. 2003;185:1208-17. DOI: 10.1128/JB.185.4.1208-1217.2003
22. Framson PE, Nittayajarn A, Merry J, Youngman P, Rubens CE. New genetic techniques for group B streptococci: high-efficiency transformation, maintenance of temperature-sensitive pWV01 plasmids, and mutagenesis with Tn917. Appl Environ Microbiol. 1997;63:3539-47.
23. Baltimore RS, Kasper DL, Baker CJ, Goroff DK. Antigenic specificity of opsonophagocytic antibodies in rabbit anti-sera to group B streptococci. J Immunol. 1977;118:673-8.
24. Thulin P, Johansson L, Low DE, Gan BS, Kotb M, McGeer A, et al. Viable group A streptococci in macrophages during acute soft tissue infection. PLoS Med. 2006;3:e53. DOI: 10.1371/journal.pmed.0030053
25. Ross RA, Madoff LC, Paoletti LC. Regulation of cell component production by growth rate in the group B Streptococcus. J Bacteriol. 1999;181:5389-94.
26. Farley MM, Harvey RC, Stull T, Smith JD, Schuchat A, Wenger JD, et al. A population-based assessment of invasive disease due to group B Streptococcus in nonpregnant adults. N Engl J Med. 1993;328:1807-11. DOI: 10.1056/NEJM199306243282503
27. Sigge A, Schmid M, Mauerer S, Spellerberg B. Heterogeneity of hemolysin expression during neonatal Streptococcus agalactiae sepsis. J Clin Microbiol. 2008;46:807-9. DOI: 10.1128/JCM.01963-07
28. Lamy MC, Zouine M, Fert J, Vergassola M, Couve E, Pellegrini E, et al. CovS/CovR of group B streptococcus: a two-component global regulatory system involved in virulence. Mol Microbiol. 2004;54:1250-68. DOI: 10.1111/j.1365-2958. 2004.04365.x
29. Jiang SM, Cieslewicz MJ, Kasper DL, Wessels MR. Regulation of virulence by a two-component system in group B streptococcus. J Bacteriol. 2005;187:1105-13. DOI: 10.1128/JB.187.3.1105- 1113.2005
30. Sumby P, Whitney AR, Graviss EA, DeLeo FR, Musser JM. Genome-wide analysis of group a streptococci reveals a mutation that modulates global phenotype and disease specificity. PLoS Pathog. 2006;2:e5. DOI: 10.1371/journal.ppat.0020005
31. Walker MJ, Hollands A, Sanderson-Smith ML, Cole JN, Kirk JK, Henningham A, et al. DNase Sda1 provides selection pressure for a switch to invasive group A streptococcal infection. Nat Med. 2007;13:981-5. DOI: 10.1038/nm1612
32. Paoletti LC, Ross RA, Johnson KD. Cell growth rate regulates expression of group B Streptococcus type III capsular polysaccharide. Infect Immun. 1996;64:1220-6.
33. Sunden-Cullberg J, Norrby-Teglund A, Routhiainen A, Rauvala H, Herman G, Tracey KJ, et al. Persistent elevation of high mobility group box-1 protein (HMGB1) in patients with severe sepsis and septic shock. Crit Care Med. 2005;33:564-73. DOI: 10.1097/01. CCM.0000155991.88802.4D
34. Wong HR, Cvijanovich N, Wheeler DS, Bigham MT, Monaco M, Odoms K, et al. Interleukin-8 as a stratification tool for interven- tional trials involving pediatric septic shock. Am J Respir Crit Care Med. 2008;178:276-82. DOI: 10.1164/rccm.200801-131OC
35. Griffiths BB, Rhee H. Effects of haemolysins of groups A and B streptococci on cardiovascular system. Microbios. 1992;69:17-27.
36. Ring A, Braun JS, Nizet V, Stremmel W, Shenep JL. Group B strep- tococcal beta-hemolysin induces nitric oxide production in murine macrophages. J Infect Dis. 2000;182:150-7. DOI: 10.1086/315681
37. Hensler ME, Miyamoto S, Nizet V. Group B streptococcal be- ta-hemolysin/cytolysin directly impairs cardiomyocyte viability and function. PLoS One. 2008;3:e2446. DOI: 10.1371/journal.pone.0002446
38. Hulse ML, Smith S, Chi EY, Pham A, Rubens CE. Effect of type III group B streptococcal capsular polysaccharide on invasion of respiratory epithelial cells. Infect Immun. 1993;61:4835-41.